Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pneumococcal vaccine conjugate 11-valent - Panacea Biotech

Next Previous
Drug Profile

Pneumococcal vaccine conjugate 11-valent - Panacea Biotech

Alternative Names: 11-valent pneumococcal polysaccharide conjugate vaccine - Panacea Biotech; NucoVac® - 11; Pneumococcal polysaccharide conjugate vaccine (adsorbed) - Panacea Biotech

Latest Information Update: 28 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Panacea Biotec
  • Class Conjugate vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pneumococcal infections

Most Recent Events

  • 28 May 2022 No recent reports of development identified for phase-I development in Pneumococcal-infections(In infants, Prevention) in India (IM, Injection)
  • 10 Oct 2019 Panacea Biotech completes a phase-I clinical trial in Pneumococcal infections (Prevention, In infants) in India (IM) (CTRI2019-04-018677)
  • 24 Apr 2019 Phase-I clinical trials in Pneumococcal infections (Prevention, In infants) in India (IM) (CTRI2019-04-018677)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top